biostudies-literatureBou Samra EANR emergence (ETTMM)423174https://www.ebi.ac.uk/biostudies/studies/S-EPMC4026849biostudies-literatureUnknown2014Despite the improvement in treatment options, chronic lymphocytic leukemia (CLL) remains an incurable disease and patients show a heterogeneous clinical course requiring therapy for many of them. In the current work, we have built a 20-gene expression (GE)-based risk score predictive for patients overall survival and improving risk classification using microarray gene expression data. GE-based risk score allowed identifying a high-risk group associated with a significant shorter overall survival (OS) and time to treatment (TTT) (P ≤ .01), comprising 19.6% and 13.6% of the patients in two independent cohorts. GE-based risk score, and NRIP1 and TCF7 gene expression remained independent prognostic factors using multivariate Cox analyses and combination of GE-based risk score together with NRIBioMed research internationalIdentification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients.PMC40268492012-E14141786SFI201212059492012-01142667Bou Samra EKlein BCommes TMoreaux JfalseIdentification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients.Despite the improvement in treatment options, chronic lymphocytic leukemia (CLL) remains an incurable disease and patients show a heterogeneous clinical course requiring therapy for many of them. In the current work, we have built a 20-gene expression (GE)-based risk score predictive for patients overall survival and improving risk classification using microarray gene expression data. GE-based risk score allowed identifying a high-risk group associated with a significant shorter overall survival (OS) and time to treatment (TTT) (P ≤ .01), comprising 19.6% and 13.6% of the patients in two independent cohorts. GE-based risk score, and NRIP1 and TCF7 gene expression remained independent prognostic factors using multivariate Cox analyses and combination of GE-based risk score together with NRI2014-01-01T00:00:00Z20142026-04-18T09:13:52.754Z2019-03-27T01:28:32ZS-EPMC40268492488331110.1155/2014/423174